Skip to main content

Peer Review reports

From: A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

Original Submission
18 Aug 2012 Submitted Original manuscript
19 Feb 2013 Reviewed Reviewer Report - m christina cox
25 Feb 2013 Reviewed Reviewer Report - Andres Forero
26 Feb 2013 Reviewed Reviewer Report - Jehan Dupuis
3 Apr 2013 Author responded Author comments - Mathias Witzens-Harig
Resubmission - Version 2
3 Apr 2013 Submitted Manuscript version 2
21 Jun 2013 Editorially accepted
25 Jun 2013 Article published 10.1186/1471-2407-13-308

You can find further information about peer review here.

Back to article page